预约演示
更新于：2025-05-24
Calcium Dobesilate
羟苯磺酸钙
更新于：2025-05-24
概要
基本信息
原研机构- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H12CaO10S2 |
InChIKeyAEWLOKQYGXDGFV-UHFFFAOYSA-N |
CAS号20123-80-2 |
关联
58
项与 羟苯磺酸钙 相关的临床试验NCT06763094
Efficacy of Calcium Dobesilate As an Alternative Method for Treatment of Menorrhagia, Comparison to Tranexamic Acid
CTR20241473
健康受试者空腹及餐后状态下口服羟苯磺酸钙片后
人体生物等效性试验
IRCT20210519051345N38
Fasted-state in vivo bioequivalence study of Calcium Dobesilate 500 mg Capsule manufactured by Abyan Pharmed compared with innovator product
100 项与 羟苯磺酸钙 相关的临床结果
登录后查看更多信息
100 项与 羟苯磺酸钙 相关的转化医学
登录后查看更多信息
100 项与 羟苯磺酸钙 相关的专利（医药）
登录后查看更多信息
589
项与 羟苯磺酸钙 相关的文献（医药）2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples
作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir
The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R2 = 0.9984).The detection and quantification limits were 1.66 x 10-6 and 2.71 x 10-5 mM, resp.The binding constant (Ka) was 9.8 x 104 M-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.
2025-04-01PHLEBOLOGY
Which dose of calcium dobesilate is more effective and safe in chronic venous insufficiency? Multicenter retrospective clinical trial
Article
作者: Uymaz, Barıs ; Arslanturk, Oguz ; Gumus, Fatih
Objectives:
This study aimed to evaluate the effectiveness and safety of different dosages of calcium dobesilate in the management of Chronic Venous Insufficiency (CVI) among patients in CEAP classes C3–C4.
Methods:
A comprehensive multicenter retrospective analysis was conducted, including patients aged 18-70 with CEAP class C3–C4 CVI. Participants were divided into two groups: one receiving 500 mg of calcium dobesilate twice daily and the other 1000 mg twice daily. Patient progress was monitored using the Global Index Score, CIVIC-20 Score, and precise measurements of ankle and calf circumferences over a 12-month period.
Results:
The higher dosage group (1000 mg twice daily) showed significant improvements in both symptom relief and edema reduction. Ankle circumference reduced notably at 6 months, while calf circumference and overall quality of life, measured by the Global Index Score, showed significant improvement by 12 months compared to the lower dosage group.
Conclusions:
Higher doses of calcium dobesilate markedly enhance the management of CVI symptoms and reduce edema more effectively than lower doses, particularly in patients with advanced CVI. These findings support the use of higher dosages for optimal treatment, though further research is needed to fully evaluate long-term safety.
2025-03-01COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
Screening hydrogen bond donors from their surface tension or refractive index to regulate the extraction efficiency of metal ions and organic compounds
作者: Sun, Yulin ; Xu, Chengjin ; Wang, Hongfei
Hydrophobic deep eutectic solvents (HDESs) are considered versatile designer solvents, characterized by a broad range of hydrogen bond acceptors (HBAs) and hydrogen bond donors (HBDs).The selection of appropriate HBDs plays a pivotal role in determining the properties of HDESs.In this work, we propose a model for screening or narrowing the range of suitable HBD reagents to enhance the extraction efficiency of metal ions and organic compoundsThis model utilizes surface tension (γt) or refractive index (nD) as the key parameters for selecting HBDs.The extraction efficiency of metal ions or organic compounds is observed to increase with a decrease in the surface tension or refractive index of the HBDs, as demonstrated in 16 different HDES systems reported in the literature, thereby confirming the reliability of the proposed method.Notably, in contrast to the COSMO-RS model, which necessitates detailed at.-level information about the pure compounds, the surface tension (γt) or refractive index (nD) model (referred to as the SA/RI model) simplifies the process by screening or narrowing the selection of HBDs based solely on these two parameters.Furthermore, by performing linear regression on γt and nD data for 31 HBDs from the literature, we establish the equation γt-(n2D-1)/(2n2D+1), which serves as a reliable tool for assessing the validity of γt and nD values for HBDs.This equation contributes to a deeper understanding of the physicochem. properties of HBDs, facilitating more effective solvent design.
100 项与 羟苯磺酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉硬化闭塞症 | 中国 | 1992-07-04 | |
| 慢性静脉功能不全 | 中国 | 1992-07-04 | |
| 高血压 | 中国 | 1992-07-04 | |
| 微血管疾病 | 中国 | 1992-07-04 | |
| 静脉炎 | 中国 | 1992-07-04 | |
| 痉挛 | 中国 | 1992-07-04 | |
| 溃疡 | 中国 | 1992-07-04 | |
| 静脉曲张 | 中国 | 1992-07-04 | |
| 糖尿病性视网膜病变 | 韩国 | 1988-01-19 | |
| 水肿 | 韩国 | 1988-01-19 | |
| 痔疮 | 韩国 | 1988-01-19 | |
| 血栓后综合征 | 韩国 | 1988-01-19 | |
| 静脉功能不全 | 韩国 | 1988-01-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病肾病 | 临床前 | - | 2018-10-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Diabetic) | 膚網積憲蓋壓積壓淵鏇(鏇觸蓋蓋鹽襯蓋糧遞鹽) = 網積艱鑰構艱鹽淵顧構 淵壓遞夢淵艱鹽壓憲蓋 (鏇壓構鑰鬱鹽蓋觸網繭 ) 更多 | - | 2009-04-01 | ||
N/A | 糖尿病性视网膜病变 type 2 diabetes | 194 | Doxium® (DX) 2g | 顧鏇繭積餘齋鹹簾願憲(遞窪顧網遞憲衊醖壓繭): P-Value = 0.0016 | 积极 | 2004-05-01 | |
Placebo | |||||||
N/A | 194 | 觸構壓鏇窪築齋觸願糧(鑰窪衊構糧蓋餘鑰夢範): P-Value = p0.044 | - | 2004-05-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用